This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): methylphenidate hydrochloride sustained release
Description: Ritalin SR is a central nervous system stimulant. The exact mechanism of action in ADHD is unknown. Ritalin SR is available as sustained release tablets where Ritalin is more slowly but as extensively absorbed as in the regular tablets.
The drug is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. In this way, Ritalin SR presumably activates the brain stem arousal system and cortex to produce its stimulant effect.
Deal Structure: Celgene entered into an agreement with Novartis in April 2000 and receives royalties on all of Novartis' Ritalin family of ADHD-related products.
Partners: Celgene Corporation
Ritalin SR News
Pink Sheet Novartis Ritalin LA clears FDA
Pink Sheet Alza Concerta
Additional information available to subscribers only: